News on ACE2 from BioPortfolio.com http://www.BioPortfolio.com Consolidated ACE2 news from BioPortfolio.com Wed, 10 Feb 2010 10:49:08 GMT en Does ACE2 contribute to the development of hypertension?http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022018&HITNO=0&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022018&THISHREF=http://c.moreover.com/click/here.pl%3fz2527443169%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022018&HITNO=0&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022018&THISHREF=http://c.moreover.com/click/here.pl%3fz2527443169%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHypertension Research: Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022025&HITNO=1&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022025&THISHREF=http://c.moreover.com/click/here.pl%3fz2527443656%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4022025&HITNO=1&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4022025&THISHREF=http://c.moreover.com/click/here.pl%3fz2527443656%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comHypertension Research: Apeiron and GSK sign an exclusive license agreement for Apeiron's therapeutic enzyme project APN01http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019592&HITNO=2&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019592&THISHREF=http://c.moreover.com/click/here.pl%3fz2526381680%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4019592&HITNO=2&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4019592&THISHREF=http://c.moreover.com/click/here.pl%3fz2526381680%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBionity.com: First Deal for Apeiron a Doozy: Getting up to $329M from GSKhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013086&HITNO=3&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013086&THISHREF=http://c.moreover.com/click/here.pl%3fz2523605415%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4013086&HITNO=3&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4013086&THISHREF=http://c.moreover.com/click/here.pl%3fz2523605415%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioWorld: First Deal for Apeiron a Doozy: Getting up to $329M from GSKhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4009978&HITNO=4&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4009978&THISHREF=http://c.moreover.com/click/here.pl%3fz2522184318%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4009978&HITNO=4&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4009978&THISHREF=http://c.moreover.com/click/here.pl%3fz2522184318%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Austria's Apeiron sells rights to early-stage lung disease drug to GlaxoSmithKline for as much as $332 millionhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014603&HITNO=5&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014603&THISHREF=http://c.moreover.com/click/here.pl%3fz2524069356%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014603&HITNO=5&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014603&THISHREF=http://c.moreover.com/click/here.pl%3fz2524069356%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Letter: GSK acquires respiratory candidatehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014190&HITNO=6&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014190&THISHREF=http://c.moreover.com/click/here.pl%3fz2523921364%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4014190&HITNO=6&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4014190&THISHREF=http://c.moreover.com/click/here.pl%3fz2523921364%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmafocus: GSK Pays Apeiron About $17.5M Up Front for Early Clinical-Stage ACE2 Candidatehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4008257&HITNO=7&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4008257&THISHREF=http://c.moreover.com/click/here.pl%3fz2521473832%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4008257&HITNO=7&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4008257&THISHREF=http://c.moreover.com/click/here.pl%3fz2521473832%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comGenetic Engineering News: ::: Apeiron and GSK sign an exclusive license agreement for Apeiron's therapeutic enzyme project APN01http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006947&HITNO=8&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006947&THISHREF=http://c.moreover.com/click/here.pl%3fz2520933461%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4006947&HITNO=8&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4006947&THISHREF=http://c.moreover.com/click/here.pl%3fz2520933461%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotech Intelligence: Apeiron And GSK Sign An Exclusive License Agreement For Apeiron's Therapeutic Enzyme Project APN01http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005394&HITNO=9&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005394&THISHREF=http://c.moreover.com/click/here.pl%3fz2520351508%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005394&HITNO=9&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005394&THISHREF=http://c.moreover.com/click/here.pl%3fz2520351508%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comTherapeutics Daily: Apeiron And GSK Sign An Exclusive License Agreement For Apeiron's Therapeutic Enzyme Project APN01http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005334&HITNO=10&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005334&THISHREF=http://c.moreover.com/click/here.pl%3fz2520327444%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4005334&HITNO=10&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4005334&THISHREF=http://c.moreover.com/click/here.pl%3fz2520327444%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Apeiron, GSK in deal for apeiron's therapeutic enzymehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004259&HITNO=11&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004259&THISHREF=http://c.moreover.com/click/here.pl%3fz2519873814%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4004259&HITNO=11&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4004259&THISHREF=http://c.moreover.com/click/here.pl%3fz2519873814%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBio Spectrum Asia: Hundred millions for biotech-licencehttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003603&HITNO=12&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003603&THISHREF=http://c.moreover.com/click/here.pl%3fz2519605530%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4003603&HITNO=12&MSIZE=13&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=ACE2&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4003603&THISHREF=http://c.moreover.com/click/here.pl%3fz2519605530%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comNews-Medical.Net: